<article title='Dehydroepiandrosterone'><paragraph><template><target>Drugbox</target><arg name="Watchedfields"><space/>changed
</arg><arg name="verifiedrevid"><space/>443682301
</arg><arg name="IUPAC_name"><space/>(3''S'',8''R'',9''S'',10''R'',13''S'',14''S'')-3-hydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[''a'']phenanthren-17-one; (1''S'',2''R'',5''S'',10''R'',11''S'',15''S'')-5-Hydroxy-2,15-dimethyltetracyclo[8.7.0.0<sup>2,7</sup>.0<sup>11,15</sup>]heptadec-7-en-14-one
</arg><arg name="image"><space/>Dehydroepiandrosteron.svg
</arg><arg name="width"><space/>
</arg><arg name="image2"><space/>Dehidroepiandrosterona3D.png
<space/></arg><arg name="legal_US"><space/>OTC
</arg><arg name="legal_CA"><space/>Rx-only
</arg><arg name="legal_AU"><space/>S4
</arg><arg name="routes_of_administration"><space/>[[Mouth|Oral]]
<space/></arg><arg name="metabolism"><space/>[[Liver|Hepatic]]
</arg><arg name="elimination_half-life"><space/>12 hours
</arg><arg name="excretion"><space/>[[Urine|Urinary]]:?%
<space/></arg><arg name="CAS_number_Ref"><space/>{{cascite|correct|??}}
</arg><arg name="CAS_number"><space/>53-43-0
</arg><arg name="ATC_prefix"><space/>A14
</arg><arg name="ATC_suffix"><space/>AA07
</arg><arg name="ATC_supplemental"><space/><br />{{ATC|G03|EA03}} (combination with [[estrogen]])
</arg><arg name="ChEBI_Ref"><space/>{{ebicite|correct|EBI}}
</arg><arg name="ChEBI"><space/>28689
</arg><arg name="DrugBank_Ref"><space/>{{drugbankcite|correct|drugbank}}
</arg><arg name="DrugBank"><space/>DB01708
</arg><arg name="PubChem"><space/>5881
</arg><arg name="IUPHAR_ligand"><space/>2370
</arg><arg name="ChemSpiderID_Ref"><space/>{{chemspidercite|correct|chemspider}}
</arg><arg name="ChemSpiderID"><space/>5670
</arg><arg name="UNII_Ref"><space/>{{fdacite|correct|FDA}}
</arg><arg name="UNII"><space/>459AG36T1B
</arg><arg name="ChEMBL_Ref"><space/>{{ebicite|correct|EBI}}
</arg><arg name="ChEMBL"><space/>90593
<space/></arg><arg name="C">19<space/></arg><arg name="H">28<space/></arg><arg name="O">2
</arg><arg name="molecular_weight"><space/>288.424 g/mol
</arg><arg name="smiles"><space/>O</arg><arg name="InChI"><space/>1/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-16,20H,4-11H2,1-2H3/t13-,14-,15-,16-,18-,19-/m0/s1
</arg><arg name="StdInChI_Ref"><space/>{{stdinchicite|correct|chemspider}}
</arg><arg name="StdInChI"><space/>1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-16,20H,4-11H2,1-2H3/t13-,14-,15-,16-,18-,19-/m0/s1
</arg><arg name="StdInChIKey_Ref"><space/>{{stdinchicite|correct|chemspider}}
</arg><arg name="StdInChIKey"><space/>FMGSKLZLMKYGDP-USOAJAOKSA-N
</arg><arg name="synonyms"><space/>(3β)-3-Hydroxyandrost-5-en-17-one
</arg><arg name="melting_point"><space/>148.5
</arg></template></paragraph><paragraph><bold>Dehydroepiandrosterone</bold>/<bold>dehydroepiandrostenedione</bold><space/>(<bold>DHEA</bold>, more correctly<space/><bold>didehydroepiandrosterone</bold>), also known as<space/><bold>androstenolone</bold><space/>or<space/><bold>prasterone</bold><space/>(<link><target>International Nonproprietary Name</target><part>INN</part></link>), as well as<space/><bold>3-hydroxyandrost-5-en-17-one</bold><space/>or<space/><bold>5-androsten-3-ol-17-one</bold>, is an important<space/><link><target>endogenous</target></link><space/><link><target>steroid hormone</target></link>.<extension extension_name='ref' name="pmid16524719"><template><target>cite journal</target><arg name="author">Mo Q, Lu SF, Simon NG<space/></arg><arg name="title">Dehydroepiandrosterone and its metabolites: differential effects on androgen receptor trafficking and transcriptional activity<space/></arg><arg name="journal">J. Steroid Biochem. Mol. Biol.<space/></arg><arg name="volume">99<space/></arg><arg name="issue">1<space/></arg><arg name="pages">50–8<space/></arg><arg name="date">April 2006<space/></arg><arg name="pmid">16524719<space/></arg><arg name="doi">10.1016/j.jsbmb.2005.11.011<space/></arg><arg name="url">http://linkinghub.elsevier.com/retrieve/pii/S0960-0760(06)00039-2</arg></template></extension><space/>It is the most abundant circulating<space/><link><target>steroid</target></link><space/>hormone in humans,<extension extension_name='ref'>William F Ganong MD, 'Review of Medical Physiology', 22nd Ed, McGraw Hill, 2005, page 362.</extension><space/>in whom it is produced in the<space/><link><target>adrenal gland</target><trail>s</trail></link>,<extension extension_name='ref'><italics>The Merck Index</italics>, 13th Edition,<space/><bold>7798</bold></extension><space/>the<space/><link><target>gonad</target><trail>s</trail></link>, and the<space/><link><target>brain</target></link>,<extension extension_name='ref'><template><target>cite book</target><arg name="author"><space/>Schulman, Robert A.<space/></arg><arg name="author2">Dean, Carolyn<space/></arg><arg name="year"><space/>2007<space/></arg><arg name="title"><space/>Solve It With Supplements<space/></arg><arg name="publisher"><space/>Rodale, Inc.<space/></arg><arg name="location"><space/>New York City<space/></arg><arg name="page"><space/>100<space/></arg><arg name="isbn"><space/>978-1-57954-942-8<space/></arg><arg name="quote"><space/>DHEA (Dehydroepiandrosterone) is a common hormone produced in the adrenal glands, the gonads, and the brain.</arg></template></extension><space/>where it functions predominantly as a<space/><link><target>metabolic intermediate</target></link><space/>in the<space/><link><target>biosynthesis</target></link><space/>of the<space/><link><target>androgen</target></link><space/>and<space/><link><target>estrogen</target></link><space/><link><target>sex steroid</target><trail>s</trail></link>.<extension extension_name='ref' name="pmid16524719"></extension><extension extension_name='ref' name="Scott1996"><template><target>cite book</target><arg name="author"><space/>Thomas Scott<space/></arg><arg name="title"><space/>Concise Encyclopedia Biology<space/></arg><arg name="url"><space/>http://books.google.com/books?id</arg><arg name="accessdate"><space/>25 May 2012<space/></arg><arg name="year"><space/>1996<space/></arg><arg name="publisher"><space/>Walter de Gruyter<space/></arg><arg name="isbn"><space/>978-3-11-010661-9<space/></arg><arg name="page"><space/>49</arg></template></extension><space/>However, DHEA also has a variety of potential biological effects in its own right, binding to an array of<space/><link><target>nuclear receptor</target><part>nuclear</part></link><space/>and<space/><link><target>cell surface receptor</target><trail>s</trail></link>,<extension extension_name='ref' name="pmid16684650"><template><target>cite journal</target><arg name="author"><space/>Webb SJ, Geoghegan TE, Prough RA, Michael Miller KK<space/></arg><arg name="title"><space/>The biological actions of dehydroepiandrosterone involves multiple receptors<space/></arg><arg name="journal"><space/>Drug Metabolism Reviews<space/></arg><arg name="volume"><space/>38<space/></arg><arg name="issue"><space/>1–2<space/></arg><arg name="pages"><space/>89–116<space/></arg><arg name="year"><space/>2006<space/></arg><arg name="pmid"><space/>16684650<space/></arg><arg name="pmc"><space/>2423429<space/></arg><arg name="doi"><space/>10.1080/03602530600569877<space/></arg><arg name="url"><space/>http://informahealthcare.com/doi/abs/10.1080/03602530600569877%20</arg></template></extension><space/>and acting as a<space/><link><target>neurosteroid</target></link>.<extension extension_name='ref' name="pmid11281367"><template><target>cite journal</target><arg name="author"><space/>Friess E, Schiffelholz T, Steckler T, Steiger A<space/></arg><arg name="title"><space/>Dehydroepiandrosterone--a neurosteroid<space/></arg><arg name="journal"><space/>European Journal of Clinical Investigation<space/></arg><arg name="volume"><space/>30 Suppl 3<space/></arg><arg name="issue"><space/></arg><arg name="pages"><space/>46–50<space/></arg><arg name="date">December 2000<space/></arg><arg name="pmid"><space/>11281367<space/></arg><arg name="doi"><space/>10.1046/j.1365-2362.2000.0300s3046.x</arg><arg name="url"><space/>http://onlinelibrary.wiley.com/resolve/openurl?genre</arg></template></extension></paragraph><heading level='2'>Medical aspects</heading><paragraph>In women with<space/><link><target>adrenal insufficiency</target></link><space/>and the healthy elderly there is insufficient evidence to support the use of DHEA.<extension extension_name='ref'><template><target>cite journal</target><arg name="last">Arlt</arg><arg name="first">W</arg><arg name="title">Dehydroepiandrosterone and ageing</arg><arg name="journal">Best practice & research. Clinical endocrinology & metabolism</arg><arg name="date">September 2004</arg><arg name="volume">18</arg><arg name="issue">3</arg><arg name="pages">363–80</arg><arg name="pmid">15261843</arg><arg name="doi">10.1016/j.beem.2004.02.006</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="last">Alkatib</arg><arg name="first">AA</arg><arg name="author2">Cosma, M</arg><arg name="author3">Elamin, MB</arg><arg name="author4">Erickson, D</arg><arg name="author5">Swiglo, BA</arg><arg name="author6">Erwin, PJ</arg><arg name="author7">Montori, VM</arg><arg name="title">A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA treatment effects on quality of life in women with adrenal insufficiency</arg><arg name="journal">The Journal of Clinical Endocrinology and Metabolism</arg><arg name="date">October 2009</arg><arg name="volume">94</arg><arg name="issue">10</arg><arg name="pages">3676–81</arg><arg name="pmid">19773400</arg><arg name="doi">10.1210/jc.2009-0672</arg></template></extension></paragraph><heading level='3'>Cancer</heading><paragraph>There is no evidence DHEA is of benefit in treating or preventing<space/><link><target>cancer</target></link>.<extension extension_name='ref' name="cancer"></extension></paragraph><heading level='3'>Strength</heading><paragraph>Evidence is inconclusive in regards to the effect of DHEA on strength in the elderly.<extension extension_name='ref'><template><target>cite journal</target><arg name="last">Baker</arg><arg name="first">WL</arg><arg name="author2">Karan, S</arg><arg name="author3">Kenny, AM</arg><arg name="title">Effect of dehydroepiandrosterone on muscle strength and physical function in older adults: a systematic review</arg><arg name="journal">Journal of the American Geriatrics Society</arg><arg name="date">June 2011</arg><arg name="volume">59</arg><arg name="issue">6</arg><arg name="pages">997–1002</arg><arg name="pmid">21649617</arg><arg name="doi">10.1111/j.1532-5415.2011.03410.x</arg></template></extension></paragraph><paragraph>In middle-aged men, no statistically significant effect of DHEA supplementation on lean body mass, strength, or<space/><link><target>testosterone</target></link><space/>levels was found in a randomized placebo-controlled trial.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Wallace, M. B.; Lim, J.; Cutler, A.; Bucci, L.<space/></arg><arg name="title">Effects of dehydroepiandrosterone vs androstenedione supplementation in men<space/></arg><arg name="journal">Medicine and Science in Sports and Exercise<space/></arg><arg name="volume">31<space/></arg><arg name="issue">12</arg><arg name="pages">1788–92<space/></arg><arg name="year">1999<space/></arg><arg name="pmid">10613429<space/></arg><arg name="doi">10.1097/00005768-199912000-00014</arg></template></extension></paragraph><heading level='3'>Memory</heading><paragraph>DHEA supplementation has not been found to be useful for memory function in normal middle aged or older adults.<extension extension_name='ref'><template><target>cite journal</target><arg name="last">Grimley Evans</arg><arg name="first">J<space/></arg><arg name="author2">Malouf, R<space/></arg><arg name="author3">Huppert, F<space/></arg><arg name="author4">van Niekerk, JK</arg><arg name="title">Dehydroepiandrosterone (DHEA) supplementation for cognitive function in healthy elderly people</arg><arg name="journal">Cochrane database of systematic reviews (Online)</arg><arg name="date">Oct 18, 2006</arg><arg name="issue">4</arg><arg name="pages">CD006221</arg><arg name="pmid">17054283</arg><arg name="doi">10.1002/14651858.CD006221</arg><arg name="editor1-last">Malouf</arg><arg name="editor1-first">Reem</arg></template></extension><space/>It has been studied as a treatment for<space/><link><target>Alzheimer's disease</target></link>, but there is no evidence that it is effective.<extension extension_name='ref'><template><target>cite journal</target><arg name="last">Fuller</arg><arg name="first">SJ<space/></arg><arg name="author2">Tan, RS<space/></arg><arg name="author3">Martins, RN</arg><arg name="title">Androgens in the etiology of Alzheimer's disease in aging men and possible therapeutic interventions</arg><arg name="journal">Journal of Alzheimer's disease : JAD</arg><arg name="date">September 2007</arg><arg name="volume">12</arg><arg name="issue">2</arg><arg name="pages">129–42</arg><arg name="pmid">17917157</arg></template></extension></paragraph><heading level='3'>Cardiovascular disease</heading><paragraph>A review in 2003 found the then-extant evidence sufficient to suggest that low serum levels of DHEAS may be associated with coronary heart disease in men, but insufficient to determine whether DHEA supplementation would have any cardiovascular benefit.<extension extension_name='ref'><template><target>cite journal</target><arg name="pmid"><space/>14609305<space/></arg><arg name="volume">58<space/></arg><arg name="issue">5<space/></arg><arg name="title">Are low dehydroepiandrosterone sulphate levels predictive for cardiovascular diseases? A review of prospective and retrospective studies<space/></arg><arg name="date">October 2003<space/></arg><arg name="journal">Acta Cardiol<space/></arg><arg name="pages">403–10<space/></arg><arg name="author">Thijs L, Fagard R, Forette F, Nawrot T, Staessen JA<space/></arg><arg name="doi"><space/>10.2143/AC.58.5.2005304</arg></template></extension></paragraph><heading level='3'>Lupus</heading><paragraph>There is some evidence of short-term benefit in those with<space/><link><target>systemic lupus erythematosus</target></link><space/>but little evidence of long-term benefit or safety.<extension extension_name='ref'><template><target>cite journal</target><arg name="last">Crosbie</arg><arg name="first">D</arg><arg name="author2">Black, C</arg><arg name="author3">McIntyre, L</arg><arg name="author4">Royle, PL</arg><arg name="author5">Thomas, S</arg><arg name="title">Dehydroepiandrosterone for systemic lupus erythematosus</arg><arg name="journal">Cochrane database of systematic reviews (Online)</arg><arg name="date">Oct 17, 2007</arg><arg name="issue">4</arg><arg name="pages">CD005114</arg><arg name="pmid">17943841</arg><arg name="doi">10.1002/14651858.CD005114.pub2</arg><arg name="editor1-last">Crosbie</arg><arg name="editor1-first">David</arg></template></extension></paragraph><heading level='3'>Body Composition</heading><paragraph>A meta-analysis of intervention studies shows that DHEA supplementation in elderly men can induce a small but significant positive effect on body composition that is strictly dependent on DHEA conversion into its bioactive metabolites such as androgens or estrogens.<extension extension_name='ref'>Dehydroepiandrosterone supplementation in elderly men: a meta-analysis study of placebo-controlled trials. http://www.ncbi.nlm.nih.gov/pubmed/23824417</extension></paragraph><heading level='2'>Side effects</heading><paragraph>DHEA is produced naturally in the human body, but the long-term effects of its use are largely unknown.<extension extension_name='ref' name="cancer"></extension><extension extension_name='ref' name="WebMD"></extension><space/>In the short term, several studies have noted few adverse effects. In a study by Chang<space/><italics>et al.</italics>, DHEA was administered at a dose of 200&amp;nbsp;mg/day for 24 weeks with slight<space/><link><target>androgenic</target></link><space/>effects noted.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Chang DM, Lan JL, Lin HY, Luo SF<space/></arg><arg name="title"><space/>Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial<space/></arg><arg name="journal"><space/>Arthritis Rheum<space/></arg><arg name="year"><space/>2002<space/></arg><arg name="volume"><space/>46<space/></arg><arg name="issue"><space/>11<space/></arg><arg name="pages"><space/>2924–2927<space/></arg><arg name="doi"><space/>10.1002/art.10615<space/></arg><arg name="pmid"><space/>12428233</arg></template></extension><space/>Another study utilized a dose up to 400&amp;nbsp;mg/day for 8 weeks with few adverse events reported.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Rabkin JG, McElhiney MC, Rabkin R, McGrath PJ, Ferrando SJ<space/></arg><arg name="title"><space/>Placebo-controlled trial of dehydroepiandrosterone (DHEA) for treatment of nonmajor depression in patients with HIV/AIDS<space/></arg><arg name="journal"><space/>Am J Psychiatry.<space/></arg><arg name="year"><space/>2006<space/></arg><arg name="volume"><space/>163<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>59–66<space/></arg><arg name="doi"><space/>10.1176/appi.ajp.163.1.59<space/></arg><arg name="pmid"><space/>16390890</arg></template></extension><space/>A longer term study followed patients dosed with 50&amp;nbsp;mg of DHEA for 12 months with the number and severity of side effects reported to be small.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Brooke AM, Kalingag LA, Miraki-Moud F, Camacho-Hübner C, Maher KT, Walker DM, Hinson JP, Monson JP<space/></arg><arg name="title"><space/>Dehydroepiandrosterone improves psychological well-being in male and female hypopituitary patients on maintenance growth hormone replacement<space/></arg><arg name="journal"><space/>J Clin Endocrinol Metab<space/></arg><arg name="year"><space/>2006<space/></arg><arg name="volume"><space/>91<space/></arg><arg name="issue"><space/>10<space/></arg><arg name="pages"><space/>3773–3779<space/></arg><arg name="doi"><space/>10.1210/jc.2006-0316<space/></arg><arg name="pmid"><space/>16849414</arg></template></extension><space/>Another study delivered a dose of 50&amp;nbsp;mg of DHEA for 10 months with no serious adverse events reported.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Villareal DT, Holloszy JO<space/></arg><arg name="title"><space/>DHEA enhances effects of weight training on muscle mass and strength in elderly women and men<space/></arg><arg name="journal"><space/>Am J Physiol Endocrinol Metab<space/></arg><arg name="year"><space/>2006<space/></arg><arg name="volume"><space/>291<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>E1003–1008<space/></arg><arg name="doi"><space/>10.1152/ajpendo.00100.2006</arg></template></extension></paragraph><paragraph>As a hormone precursor, there has been a smattering of reports of side effects possibly caused by the hormone metabolites of DHEA.<extension extension_name='ref' name="WebMD"><template><target>cite web</target><arg name="url">http://www.medscape.com/druginfo/dosage?cid</arg><arg name="title">DHEA Oral</arg><arg name="last">Medscape</arg><arg name="year">2010</arg><arg name="work">Drug Reference</arg><arg name="publisher">WebMD LLC.</arg><arg name="accessdate">18 February 2010</arg></template></extension><extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.nlm.nih.gov/medlineplus/druginfo/natural/patient-dhea.html#Safety</arg><arg name="title">DHEA</arg><arg name="last">Medline Plus</arg><arg name="work">Drugs and Supplements Information</arg><arg name="publisher">National Library of Medicine</arg><arg name="accessdate">18 February 2010</arg></template></extension></paragraph><paragraph>It is not known whether DHEA is safe for long-term use. Some researchers believe DHEA supplements might actually raise the risk of<space/><link><target>breast cancer</target></link>,<space/><link><target>prostate cancer</target></link>,<space/><link><target>heart disease</target></link>,<space/><link><target>diabetes</target></link>,<extension extension_name='ref' name="WebMD"></extension><space/>and<space/><link><target>stroke</target></link>. DHEA may stimulate tumor growth in types of cancer that are sensitive to hormones, such as some types of breast, uterine, and prostate cancer.<extension extension_name='ref' name="WebMD"></extension><space/>DHEA may increase prostate swelling in men with<space/><link><target>benign prostatic hyperplasia</target></link><space/>(BPH), an enlarged prostate gland.<extension extension_name='ref' name="cancer"></extension></paragraph><paragraph>DHEA is a<space/><link><target>steroid hormone</target></link>. High doses may cause aggressiveness, irritability, trouble sleeping, and the growth of body or facial hair on women.<extension extension_name='ref' name="cancer"></extension><space/>It also may stop menstruation and lower the levels of<space/><link><target>High-density lipoprotein</target><part>HDL</part></link><space/>(&quot;good&quot; cholesterol), which could raise the risk of heart disease.<extension extension_name='ref' name="cancer"></extension><space/>Other reported side effects include acne, heart rhythm problems, liver problems, hair loss (from the scalp), and oily skin. It may also alter the body's regulation of blood sugar.<extension extension_name='ref' name="cancer"></extension></paragraph><paragraph>DHEA should not be used with<space/><link><target>tamoxifen</target></link>, as it may promote tamoxifen resistance.<extension extension_name='ref' name="cancer"></extension><space/>Patients on hormone replacement therapy may have more estrogen-related side effects when taking DHEA. This supplement may also interfere with other medicines, and potential interactions between it and drugs and herbs should be considered. Always tell your doctor and pharmacist about any supplements and herbs you are taking.<extension extension_name='ref' name="cancer"><template><target>cite book</target><arg name="publisher">[[American Cancer Society]]<space/></arg><arg name="work">American Cancer Society Complete Guide to Complementary and Alternative Cancer Therapies<space/></arg><arg name="edition">2nd<space/></arg><arg name="year">2009<space/></arg><arg name="isbn">9780944235713<space/></arg><arg name="editor">Ades TB<space/></arg><arg name="pages">729–733<space/></arg><arg name="title">DHEA</arg></template></extension></paragraph><paragraph>DHEA is possibly unsafe for individuals experiencing the following conditions: pregnancy and breast-feeding, hormone sensitive conditions, liver problems, diabetes, depression or mood disorders,<space/><link><target>polycystic ovarian syndrome</target></link><space/>(PCOS), or cholesterol problems.<extension extension_name='ref'><template><target>cite web</target><arg name="title">DHEA: Side effects and safety</arg><arg name="url">http://www.webmd.com/vitamins-supplements/ingredientmono-331-DHEA.aspx?activeIngredientId</arg><arg name="publisher">WebMD</arg><arg name="accessdate">24 July 2012</arg></template></extension><space/>Individuals experiencing any of these conditions should consult with a doctor before taking.</paragraph><heading level='2'>Dehydroepiandrosterone sulfate</heading><paragraph><template><target>Main</target><arg>Dehydroepiandrosterone sulfate</arg></template><link><target>Dehydroepiandrosterone sulfate</target></link><space/>(DHEAS) is the sulfate ester of DHEA. This conversion is reversibly catalyzed by<space/><link><target>sulfotransferase</target></link><space/>(<link><target>SULT2A1</target></link>) primarily in the adrenals, the<space/><link><target>liver</target></link>, and<space/><link><target>small intestine</target></link>. In the blood, most DHEA is found as DHEAS with levels that are about 300 times higher than those of free DHEA. Orally ingested DHEA is converted to its sulfate when passing through intestines and liver. Whereas DHEA levels naturally reach their peak in the early morning hours, DHEAS levels show no<space/><link><target>Circadian rhythm</target><part>diurnal</part></link><space/>variation. From a practical point of view, measurement of DHEAS is preferable to DHEA, as levels are more stable.<template><target>Citation needed</target><arg name="date">January 2009</arg></template></paragraph><heading level='2'>Production</heading><paragraph><link><target>File:Steroidogenesis.svg</target><part>thumb</part><part>right</part><part>Comprehensive overview of<space/><link><target>steroidogenesis</target></link>, showing DHEA at left among the androgens.</part></link>DHEA is produced from cholesterol through two<space/><link><target>cytochrome P450</target></link><space/>enzymes. Cholesterol is converted to<space/><link><target>pregnenolone</target></link><space/>by the enzyme<space/><link><target>P450 scc</target></link><space/>(<link><target>side chain</target></link><space/>cleavage); then another enzyme,<space/><link><target>CYP17A1</target></link>, converts<space/><link><target>pregnenolone</target></link><space/>to<space/><link><target>17-Hydroxypregnenolone</target><part>17-hydroxypregnenolone</part></link><space/>and then to DHEA.<extension extension_name='ref'>Harper's illustrated Biochemistry, 27th edition, Ch.41 &quot;The Diversity of the Endocrine system&quot;</extension></paragraph><heading level='2'>Mechanism of action</heading><paragraph>Although it predominantly functions as an endogenous<space/><link><target>precursor (biochemistry)</target><part>precursor</part></link><space/>to more<space/><link><target>potency (pharmacology)</target><part>potent</part></link><space/>androgens such as testosterone and DHT, DHEA has been found to possess some degree of<space/><link><target>androgen</target><trail>ic</trail></link><space/>activity in its own right, acting as a low<space/><link><target>affinity (pharmacology)</target><part>affinity</part></link><space/>(K<xhtml:sub>i</xhtml:sub><space/>= 1 M), weak<space/><link><target>partial agonist</target></link><space/>of the<space/><link><target>androgen receptor</target></link>. However, its<space/><link><target>intrinsic activity</target></link><space/>at the receptor is quite weak, and on account of that, due to<space/><link><target>competitive inhibition</target><part>competition</part></link><space/>for<space/><link><target>molecular binding</target><part>binding</part></link><space/>with<space/><link><target>full agonist</target><trail>s</trail></link><space/>like testosterone, it can actually behave more like an antagonist depending on circulating testosterone and<space/><link><target>dihydrotestosterone</target></link><space/>(DHT) levels, and hence, like an<space/><link><target>antiandrogen</target></link>. However, its affinity for the receptor is very low, and for that reason, is unlikely to be of much significance under normal circumstances.<extension extension_name='ref' name="pmid15994348"><template><target>cite journal</target><arg name="author"><space/>Chen F, Knecht K, Birzin E<space/></arg><arg name="title"><space/>Direct agonist/antagonist functions of dehydroepiandrosterone<space/></arg><arg name="journal"><space/>Endocrinology<space/></arg><arg name="volume"><space/>146<space/></arg><arg name="issue"><space/>11<space/></arg><arg name="pages"><space/>4568–76<space/></arg><arg name="date">November 2005<space/></arg><arg name="pmid"><space/>15994348<space/></arg><arg name="doi"><space/>10.1210/en.2005-0368<space/></arg><arg name="url"><space/>http://endo.endojournals.org/cgi/pmidlookup?view</arg><arg name="display-authors">etal</arg></template></extension><extension extension_name='ref' name="pmid16159155"><template><target>cite journal</target><arg name="author"><space/>Gao W, Bohl CE, Dalton JT<space/></arg><arg name="title"><space/>Chemistry and structural biology of androgen receptor<space/></arg><arg name="journal"><space/>Chemical Reviews<space/></arg><arg name="volume"><space/>105<space/></arg><arg name="issue"><space/>9<space/></arg><arg name="pages"><space/>3352–70<space/></arg><arg name="date">September 2005<space/></arg><arg name="pmid"><space/>16159155<space/></arg><arg name="pmc"><space/>2096617<space/></arg><arg name="doi"><space/>10.1021/cr020456u<space/></arg><arg name="url"><space/>http://dx.doi.org/10.1021/cr020456u</arg></template></extension></paragraph><paragraph>In addition to its affinity for the androgen receptor, DHEA has also been found to bind to and activate the<space/><link><target>Estrogen receptor alpha</target><part>ER</part></link><space/>and<space/><link><target>Estrogen receptor beta</target><part>ER</part></link><space/><link><target>estrogen receptor</target><trail>s</trail></link><space/>with K<xhtml:sub>i</xhtml:sub><space/>values of 1.1 M and 0.5 M, respectively, and<space/><link><target>EC50</target><part>EC<xhtml:sub>50</xhtml:sub></part></link><space/>values of &gt;1 M and 200 nM, respectively. Though it was found to be a partial agonist of the ER with a maximal efficacy of 30-70%, the concentrations required for this degree of activation make it unlikely that the activity of DHEA at this receptor is physiologically meaningful. Remarkably however, DHEA acts as a full agonist of the ER with a maximal response similar to or actually slightly greater than that of<space/><link><target>estradiol</target></link>, and its levels in circulation and local tissues in the human body are high enough to activate the receptor to the same degree as that seen with circulating estradiol levels at somewhat higher than their maximal, non-<link><target>ovulation</target><part>ovulatory</part></link><space/>concentrations; indeed, when combined with estradiol with both at levels equivalent to those of their physiological concentrations, overall activation of the ER was doubled. As such, it has been proposed that DHEA may be an important and potentially major endogenous<space/><link><target>estrogen</target></link><space/>in the body.<extension extension_name='ref' name="pmid16684650"></extension><extension extension_name='ref' name="pmid15994348"></extension></paragraph><paragraph>Unlike the case of the androgen and estrogen receptors, DHEA does not bind to or activate the<space/><link><target>progesterone receptor</target><part>progesterone</part></link>,<space/><link><target>glucocorticoid receptor</target><part>glucocorticoid</part></link>, or<space/><link><target>mineralocorticoid receptor</target><trail>s</trail></link>.<extension extension_name='ref' name="pmid15994348"></extension><extension extension_name='ref' name="pmid21747041"><template><target>cite journal</target><arg name="author"><space/>Lindschau C, Kirsch T, Klinge U, Kolkhof P, Peters I, Fiebeler A<space/></arg><arg name="title"><space/>Dehydroepiandrosterone-induced phosphorylation and translocation of FoxO1 depend on the mineralocorticoid receptor<space/></arg><arg name="journal"><space/>Hypertension<space/></arg><arg name="volume"><space/>58<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>471–8<space/></arg><arg name="date">September 2011<space/></arg><arg name="pmid"><space/>21747041<space/></arg><arg name="doi"><space/>10.1161/HYPERTENSIONAHA.111.171280<space/></arg><arg name="url"><space/>http://hyper.ahajournals.org/cgi/pmidlookup?view</arg></template></extension></paragraph><paragraph>Other<space/><link><target>nuclear receptor</target></link><space/>targets of DHEA include the<space/><link><target>Peroxisome proliferator-activated receptor</target><part>PPAR</part></link>,<space/><link><target>pregnane X receptor</target><part>PXR</part></link>, and<space/><link><target>Constitutive androstane receptor</target><part>CAR</part></link>. In addition, it has been found to directly act on several<space/><link><target>cell surface receptor</target><part>membrane receptor</part><trail>s</trail></link>, including the<space/><link><target>NMDA receptor</target></link><space/>as a<space/><link><target>positive allosteric modulator</target></link>, the<space/><link><target>GABAA receptor</target><part>GABA<xhtml:sub>A</xhtml:sub><space/>receptor</part></link><space/>as a<space/><link><target>negative allosteric modulator</target></link>, and the<space/><link><target>sigma-1 receptor</target><part><xhtml:sub>1</xhtml:sub><space/>receptor</part></link><space/>as an<space/><link><target>agonist</target></link>. It is these actions that have conferred the label of a &quot;neurosteroid&quot; upon DHEA. Finally, DHEA is thought to regulate a handful of other<space/><link><target>protein</target><trail>s</trail></link><space/>via indirect, genomic mechanisms, including the<space/><link><target>enzyme</target><trail>s</trail></link><space/><link><target>CYP2C11</target><part>P4502C11</part></link><space/>and<space/><link><target>11-hydroxysteroid dehydrogenase type 1</target><part>11-HSD1</part></link>the latter of which is essential for the biosynthesis of the<space/><link><target>glucocorticoid</target><trail>s</trail></link><space/>such as<space/><link><target>cortisol</target></link><space/>and has been suggested to be involved in the<space/><link><target>antiglucocorticoid</target></link><space/>effects of DHEAand the<space/><link><target>Carrier protein</target><part>carrier</part></link><space/><link><target>Insulin-like growth factor-binding protein 1</target><part>IGFBP1</part></link>.<extension extension_name='ref' name="pmid15994348"></extension><extension extension_name='ref' name="pmid8035785"><template><target>cite journal</target><arg name="author"><space/>Kalimi M, Shafagoj Y, Loria R, Padgett D, Regelson W<space/></arg><arg name="title"><space/>Anti-glucocorticoid effects of dehydroepiandrosterone (DHEA)<space/></arg><arg name="journal"><space/>Molecular and Cellular Biochemistry<space/></arg><arg name="volume"><space/>131<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>99–104<space/></arg><arg name="date">February 1994<space/></arg><arg name="pmid"><space/>8035785<space/></arg><arg name="doi"><space/>10.1007/BF00925945</arg><arg name="url"><space/></arg></template></extension></paragraph><heading level='2'>Biological role</heading><paragraph>DHEA and other adrenal androgens such as<space/><link><target>androstenedione</target></link>, although relatively weak androgens, are responsible for the androgenic effects of<space/><link><target>adrenarche</target></link>, such as early<space/><link><target>pubic hair</target><part>pubic</part></link><space/>and<space/><link><target>axillary hair</target></link><space/>growth, adult-type<space/><link><target>body odor</target></link>, increased oiliness of hair and skin, and mild<space/><link><target>acne</target></link>.<extension extension_name='ref' name="PescovitzEugster2004"><template><target>cite book</target><arg name="author1">Ora Hirsch Pescovitz</arg><arg name="author2">Erica A. Eugster</arg><arg name="title">Pediatric Endocrinology: Mechanisms, Manifestations, and Management</arg><arg name="url">http://books.google.com/books?id</arg><arg name="year">2004</arg><arg name="publisher">Lippincott Williams & Wilkins</arg><arg name="isbn">978-0-7817-4059-3</arg><arg name="pages">362–</arg></template></extension><extension extension_name='ref' name="Lifshitz2006"><template><target>cite book</target><arg name="author">Fima Lifshitz</arg><arg name="title">Pediatric Endocrinology: Growth, Adrenal, Sexual, Thyroid, Calcium, and Fluid Balance Disorders</arg><arg name="url">http://books.google.com/books?id</arg><arg name="date">26 December 2006</arg><arg name="publisher">CRC Press</arg><arg name="isbn">978-1-4200-4272-6</arg><arg name="pages">289–</arg></template></extension><extension extension_name='ref' name="Salhan2011"><template><target>cite book</target><arg name="author">Sudha Salhan</arg><arg name="title">Textbook of Gynecology</arg><arg name="url">http://books.google.com/books?id</arg><arg name="date">1 August 2011</arg><arg name="publisher">JP Medical Ltd</arg><arg name="isbn">978-93-5025-369-4</arg><arg name="pages">94–</arg></template></extension><space/>Women with<space/><link><target>complete androgen insensitivity syndrome</target></link><space/>(CAIS), who have a non-functional<space/><link><target>androgen receptor</target></link><space/>(AR) and are immune to the androgenic effects of DHEA and other androgens, have absent or only sparse/scanty pubic and axillary hair and<space/><link><target>body hair</target></link><space/>in general, demonstrating the role of DHEA,<space/><link><target>testosterone</target></link>, and other androgens in body hair development at both adrenarche and<space/><link><target>pubarche</target></link>.<extension extension_name='ref' name="LaverySanfilippo2012"><template><target>cite book</target><arg name="author1">J.P. Lavery</arg><arg name="author2">J.S. Sanfilippo</arg><arg name="title">Pediatric and Adolescent Obstetrics and Gynecology</arg><arg name="url">http://books.google.com/books?id</arg><arg name="date">6 December 2012</arg><arg name="publisher">Springer Science & Business Media</arg><arg name="isbn">978-1-4612-5064-7</arg><arg name="pages">45–</arg></template></extension><extension extension_name='ref' name="NussbaumMcInnes2015"><template><target>cite book</target><arg name="author1">Robert L. Nussbaum</arg><arg name="author2">Roderick R. McInnes</arg><arg name="author3">Huntington F Willard</arg><arg name="title">Thompson & Thompson Genetics in Medicine</arg><arg name="url">http://books.google.com/books?id</arg><arg name="date">28 April 2015</arg><arg name="publisher">Elsevier Health Sciences</arg><arg name="isbn">978-0-323-39206-8</arg><arg name="pages">102–</arg></template></extension><extension extension_name='ref' name="SetchellHudson2013"><template><target>cite book</target><arg name="author1">Marcus E Setchell</arg><arg name="author2">C. N. Hudson</arg><arg name="title">Shaw's Textbook of Operative Gynaecology</arg><arg name="url">http://books.google.com/books?id</arg><arg name="date">4 April 2013</arg><arg name="publisher">Elsevier Health Sciences</arg><arg name="isbn">81-312-3481-9</arg><arg name="pages">129–</arg></template></extension><extension extension_name='ref' name="BissonnetteDalens2006"><template><target>cite book</target><arg name="author1">Bruno Bissonnette</arg><arg name="author2">Bernard Dalens</arg><arg name="title">Syndromes: Rapid Recognition and Perioperative Implications</arg><arg name="url">http://books.google.com/books?id</arg><arg name="date">20 July 2006</arg><arg name="publisher">McGraw Hill Professional</arg><arg name="isbn">978-0-07-135455-4</arg><arg name="page">184</arg></template></extension></paragraph><paragraph>As a<space/><link><target>neurosteroid</target></link>, DHEA has important effects on<space/><link><target>neurological</target></link><space/>and<space/><link><target>psychological</target></link><space/>functioning.<extension extension_name='ref' name="Weizman2008"><template><target>cite book</target><arg name="author">Abraham Weizman</arg><arg name="title">Neuroactive Steroids in Brain Function, Behavior and Neuropsychiatric Disorders: Novel Strategies for Research and Treatment</arg><arg name="url">http://books.google.com/books?id</arg><arg name="date">1 February 2008</arg><arg name="publisher">Springer Science & Business Media</arg><arg name="isbn">978-1-4020-6854-6</arg><arg name="pages">241–</arg></template></extension><extension extension_name='ref' name="GravanisMellon2011"><template><target>cite book</target><arg name="author1">Achille G. Gravanis</arg><arg name="author2">Synthia H. Mellon</arg><arg name="title">Hormones in Neurodegeneration, Neuroprotection, and Neurogenesis</arg><arg name="url">http://books.google.com/books?id</arg><arg name="date">24 June 2011</arg><arg name="publisher">John Wiley & Sons</arg><arg name="isbn">978-3-527-63397-5</arg><arg name="pages">349–</arg></template></extension><extension extension_name='ref'><template><target>cite book</target><arg name="title">Sex difference in the human brain, their underpinnings and implications</arg><arg name="url">http://books.google.com/books?id</arg><arg name="date">3 December 2010</arg><arg name="publisher">Elsevier</arg><arg name="isbn">978-0-444-53631-0</arg><arg name="pages">127–</arg></template></extension></paragraph><heading level='2'>Measurement</heading><paragraph>As almost all DHEA is derived from the adrenal glands, blood measurements of DHEAS/DHEA are useful to detect excess adrenal activity as seen in adrenal cancer or hyperplasia, including certain forms of<space/><link><target>congenital adrenal hyperplasia</target></link>. Women with<space/><link><target>polycystic ovary syndrome</target></link><space/>tend to have elevated levels of DHEAS.<extension extension_name='ref'><template><target>cite journal</target><arg name="volume"><space/>48<space/></arg><arg name="year"><space/>2003<space/></arg><arg name="journal"><space/>Annales Academiae Medicae Bialostocensis<space/></arg><arg name="title"><space/>Incidence of elevated LH/FSH ratioin polycystic ovary syndrome women with normo- and hyperinsulinemia<space/></arg><arg name="author"><space/>Banaszewska B, Spaczyński RZ, Pelesz M, Pawelczyk L</arg></template></extension></paragraph><heading level='2'>Increasing endogenous production</heading><paragraph>Regular<space/><link><target>exercise</target></link><space/>is known to increase DHEA production in the body.<extension extension_name='ref'><template><target>Cite journal</target><arg name="journal"><space/>Eur. J. Appl. Physiol. Occup. Physiol.<space/></arg><arg name="year"><space/>1998<space/></arg><arg name="volume"><space/>78<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>466–471<space/></arg><arg name="doi"><space/>10.1007/s004210050447<space/></arg><arg name="pmid"><space/>9809849<space/></arg><arg name="last1"><space/>Filaire<space/></arg><arg name="first1"><space/>E<space/></arg><arg name="last2"><space/>Duché<space/></arg><arg name="first2"><space/>P<space/></arg><arg name="last3"><space/>Lac<space/></arg><arg name="first3"><space/>G<space/></arg><arg name="title"><space/>Effects of amount of training on the saliva concentrations of cortisol, dehydroepiandrosterone and on the dehydroepiandrosterone: Cortisol concentration ratio in women over 16 weeks of training</arg></template></extension><extension extension_name='ref'><template><target>Cite journal</target><arg name="journal"><space/>J. Gerontol. A. Biol. Sci. Med. Sci.<space/></arg><arg name="year"><space/>2002<space/></arg><arg name="volume"><space/>57<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>B158–165<space/></arg><arg name="doi"><space/>10.1093/gerona/57.4.B158<space/></arg><arg name="title"><space/>Hormonal Responses to Endurance and Resistance Exercise in Females Aged 19-69 Years<space/></arg><arg name="last1"><space/>Copeland<space/></arg><arg name="first1"><space/>J. L.<space/></arg><arg name="last2"><space/>Consitt<space/></arg><arg name="first2"><space/>L. A.<space/></arg><arg name="last3"><space/>Tremblay<space/></arg><arg name="first3"><space/>M. S.</arg></template></extension><space/><link><target>Calorie restriction</target></link><space/>has also been shown to increase DHEA in primates.<extension extension_name='ref'><template><target>Cite journal</target><arg name="last">Mattison<space/></arg><arg name="first">Julie A.<space/></arg><arg name="last2">Lane<space/></arg><arg name="first2">Mark A.<space/></arg><arg name="last3">Roth<space/></arg><arg name="first3">George S.<space/></arg><arg name="last4">Ingram<space/></arg><arg name="first4">Donald K.<space/></arg><arg name="year">2003<space/></arg><arg name="title">Calorie restriction in rhesus monkeys<space/></arg><arg name="journal">Experimental Gerontology<space/></arg><arg name="volume">38<space/></arg><arg name="issue">1–2<space/></arg><arg name="pages">35–46<space/></arg><arg name="doi">10.1016/S0531-5565(02)00146-8<space/></arg><arg name="pmid">12543259<space/></arg><arg name="postscript"><space/></arg></template>.</extension><space/>Some theorize that the increase in endogenous DHEA brought about by calorie restriction is partially responsible for the longer life expectancy known to be associated with calorie restriction.<extension extension_name='ref'><template><target>Cite journal</target><arg name="last">Roberts<space/></arg><arg name="first">E.<space/></arg><arg name="title">The importance of dehydroepiandrosterone sulfate in the blood of primates: a longer and healthier life?<space/></arg><arg name="journal">[[Biochemical Pharmacology]]<space/></arg><arg name="year">1999<space/></arg><arg name="volume">57<space/></arg><arg name="issue">4<space/></arg><arg name="pages">329–346<space/></arg><arg name="doi">10.1016/S0006-2952(98)00246-9<space/></arg><arg name="pmid">9933021<space/></arg><arg name="postscript"><space/></arg></template>.</extension>Catalpol and a combination of acetyl-carnitine and propionyl-carnitine on 1:1 ratio also improves endogenous DHEA production and release due to direct cholinergic stimulation of CRH release and an increase of IGF-1 expression respectively.</paragraph><heading level='2'>Isomers</heading><paragraph>The term &quot;dehydroepiandrosterone&quot; is ambiguous chemically because it does not include the specific positions within epiandrosterone at which hydrogen atoms are missing. DHEA has a number of naturally occurring isomers that may have similar pharmacological effects. Some isomers of DHEA are<space/><link><target>1-Dehydroepiandrosterone</target><part>1-dehydroepiandrosterone</part></link><space/>and<space/><link><target>4-Dehydroepiandrosterone</target><part>4-dehydroepiandrosterone</part></link>. These isomers are also technically DHEA, since they are dehydroepiandrosterones in which hydrogens are removed from the<space/><link><target>epiandrosterone</target></link><space/>skeleton.</paragraph><heading level='2'>Society and culture</heading><heading level='3'>Legality</heading><heading level='4'>United States</heading><paragraph>DHEA is legal to sell in the United States as a dietary supplement. It is currently<space/><link><target>Grandfather clause</target><part>grandfathered</part></link><space/>in as an &quot;Old Dietary Ingredient&quot; being on sale prior to 1994. DHEA is specifically exempted from the Anabolic Steroid Control Act of 1990 and 2004<extension extension_name='ref'><template><target>cite web</target><arg name="url"><space/>http://www.deadiversion.usdoj.gov/fed_regs/rules/2005/fr1216.htm<space/></arg><arg name="title"><space/>Drug Scheduling Actions - 2005<space/></arg><arg name="publisher"><space/>[[Drug Enforcement Administration]]</arg></template></extension>It is banned from use in athletic competition.</paragraph><heading level='4'>Canada</heading><paragraph>In Canada, DHEA is a Controlled Drug listed under Section 23 of Schedule IV of the<space/><italics>Controlled Drugs and Substances Act</italics><extension extension_name='ref'><link type='external' href='http://webprod.hc-sc.gc.ca/nhpid-bdipsn/ingredReq.do?id=4639&amp;amp;lang=eng'>Health Canada, DHEA listing in the Ingredient Database</link></extension><space/>and as such is available by prescription only.</paragraph><heading level='4'>Australia</heading><paragraph>In Australia, a prescription is required to buy DHEA, where it is also comparatively expensive compared to off-the-shelf purchases in US supplement shops. Australian customs classify DHEA as an &quot;anabolic steroid[s] or precursor[s]&quot; and, as such, it is only possible to carry DHEA into the country through customs if one possesses an import permit which may be obtained if one has a valid prescription for the hormone.<extension extension_name='ref'><link type='external' href='http://www.tga.gov.au/consumers/personal-importation-scheme.htm'>Therapeutic Goods Administration, Personal Importation Scheme</link></extension></paragraph><heading level='4'>Sports and athletics</heading><paragraph>DHEA is a prohibited substance under the World Anti-Doping Code of the World Anti-Doping Agency,<extension extension_name='ref'><link type='external' href='http://www.wada-ama.org/en/'>World Anti-Doping Agency</link></extension><space/>which manages drug testing for Olympics and other sports. In January 2011,<space/><link><target>National Basketball Association</target><part>NBA</part></link><space/>player<space/><link><target>O.J. Mayo</target></link><space/>was given a 10-game suspension after testing positive for DHEA. Mayo termed his use of DHEA as &quot;an honest mistake,&quot; saying the DHEA was in an<space/><link><target>over-the-counter</target></link><space/>supplement and that he was unaware the supplement was banned by the NBA.<extension extension_name='ref'><link type='external' href='http://sports.espn.go.com/nba/news/story?id=6065824'>Memphis Grizzlies' O.J. Mayo gets 10-game drug suspension</link>,<space/><italics>ESPN</italics>, January 27, 2011.</extension><space/>Mayo is the seventh player to test positive for performance-enhancing drugs since the league began testing in 1999. Rashard Lewis, then with the Orlando Magic, tested positive for DHEA and was suspended 10 games before the start of the 2009-10 season.<extension extension_name='ref'><link type='external' href='http://www.commercialappeal.com/news/2011/jan/27/oj-mayo-suspended-10-games-violating-nba-anti-drug/'>Memphis Grizzlies' O.J. Mayo suspended 10 games for violating NBA anti-drug program</link></extension><space/>2008 Olympic 400 meter champion<space/><link><target>Lashawn Merritt</target></link><space/>has also tested positive for DHEA and was banned from the sport for 21 months.<extension extension_name='ref'><template><target>cite web</target><arg name="url"><space/>http://news.bbc.co.uk/sport1/hi/athletics/8638727.stm<space/></arg><arg name="title"><space/>US 400m star LaShawn Merritt fails drug test<space/></arg><arg name="publisher"><space/>[[BBC Sport]]<space/></arg><arg name="date"><space/>22 April 2010</arg></template></extension><space/><link><target>Yulia Efimova</target></link>, Russian Olympic Medal-Winning Swimmer 2013, had positive test for DHEA.<extension extension_name='ref'><link type='external' href='http://en.ria.ru/sports/20140117/186628638/Russian-Olympic-Medal-Winning-Swimmer-Yefimova-Fails-Doping-Test.html'>Russian Olympic Medal-Winning Swimmer Efimova Fails Doping Test Report</link></extension></paragraph><heading level='3'>Marketing</heading><paragraph>In the United States, DHEA or DHEAS have been advertised with claims that they may be beneficial for a wide variety of ailments. DHEA and DHEAS are readily available in the United States, where they are marketed as over-the-counter<space/><link><target>dietary supplement</target><trail>s</trail></link>.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Calfee, R.; Fadale, P.<space/></arg><arg name="title">Popular ergogenic drugs and supplements in young athletes<space/></arg><arg name="journal">Pediatrics<space/></arg><arg name="volume">117<space/></arg><arg name="issue">3</arg><arg name="pages">e577–89<space/></arg><arg name="date">March 2006<space/></arg><arg name="pmid">16510635<space/></arg><arg name="doi">10.1542/peds.2005-1429<space/></arg><arg name="url"></arg><arg name="quote">In 2004, a new Steroid Control Act that placed androstenedione under Schedule III of controlled substances effective January 2005 was signed. DHEA was not included in this act and remains an over-the-counter nutritional supplement.</arg></template></extension></paragraph><heading level='2'>See also</heading><list type='bullet'><listitem><link><target>3-Androstanediol</target></link></listitem><listitem><link><target>Androsterone</target></link></listitem><listitem><link><target>Etiocholanolone</target></link></listitem><listitem><link><target>List of unproven and disproven cancer treatments</target></link></listitem><listitem><link><target>Pregnenolone sulfate</target></link></listitem></list><heading level='2'>References</heading><paragraph><template><target>Reflist</target><arg>30em</arg></template></paragraph><heading level='2'>External links</heading><preblock><preline></preline><preline></preline><preline></preline><preline></preline><preline></preline></preblock><list type='bullet'><listitem><link type='external' href='http://www.mayoclinic.com/health/dhea/NS_patient-dhea'>Information on DHEA from the Mayo Clinic</link></listitem><listitem><link type='external' href='http://content.nejm.org/cgi/content/abstract/355/16/1647'>DHEA in elderly women and DHEA or testosterone in elderly men</link>, published in the<space/><italics><link><target>New England Journal of Medicine</target></link></italics><space/>in 2006. &quot;Neither DHEA nor low-dose testosterone replacement in elderly people has physiologically relevant beneficial effects on body composition, physical performance, insulin sensitivity, or quality of life.&quot;</listitem><listitem><link type='external' href='http://skepdic.com/dhea.html'>DHEA, from the Skeptic's Dictionary</link></listitem><listitem><link type='external' href='http://chemsub.online.fr/name/dehydroepiandrosterone.html'>ChemSub Online: Dehydroepiandrosterone - DHEA</link></listitem></list><paragraph><template><target>Hormones</target></template><template><target>Steroid hormones</target></template><template><target>Androgens</target></template><template><target>Androgenics</target></template><template><target>Estrogenics</target></template><template><target>GABAergics</target></template><template><target>Glutamatergics</target></template><template><target>Sigmaergics</target></template><template><target>Nuclear receptor ligands</target></template></paragraph><paragraph><link><target>Category:Androgens</target></link><link><target>Category:Estrogens</target></link><link><target>Category:Endogenous androgenic substances</target></link><link><target>Category:Dietary supplements</target></link><link><target>Category:Hormones of the hypothalamus-pituitary-gonad axis</target></link><link><target>Category:GABAA receptor negative allosteric modulators</target></link><link><target>Category:Neurosteroids</target></link><link><target>Category:NMDA receptor agonists</target></link><link><target>Category:Pheromones</target></link><link><target>Category:Pregnane X receptor agonists</target></link><link><target>Category:Sex hormones</target></link><link><target>Category:Sigma agonists</target></link></paragraph></article>